BETIMOL (nda020439)- (0.25%,0.5%)

Generic Name	TIMOLOL	Innovator	THEA PHARMA
Dosage	0.25%,0.5%
ParaIV Filing	No	505(b)2 Filing	Yes
Last Patent Expiry	2010-Jul-27	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	Betimol® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
2	0	0

Other Developers

Total Other Developers	1

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
0.25%	**	**	-	-	-
0.5%	**	**	Up	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of BETIMOL